Elevance Health Beat Street Estimates On Q2 Profit And Revenue, Sticks To Annual Guidance
Elevance Health Beat Street Estimates On Q2 Profit And Revenue, Sticks To Annual Guidance
Elevance Health Inc. (NYSE:ELV) reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.
Elevance Health Inc.（纽交所：ELV）报告了第二季度营收为432亿美元，同比下降0.4％，略高于430.5亿美元的共识。
The decrease was driven by attrition in Medicaid membership, partially offset by higher premium yields reflecting the medical cost trend and growth in CarelonRx product revenue related to members served.
这种下降是由于医疗补助会员流失，部分抵消了医疗成本趋势和 CarelonRx 产品收入增长所反映的更高保费收益所致。
Related: Morgan Stanley Says Elevance Health's Growth Attributed To Consistent Performance But Undervalued.
相关：摩根士丹利表示 Elevance Health 的增长归因于一贯的表现，但估值被低估。
Premiums fell 3.2% to $35.42 billion, and product revenue rose 14% to $5.53 billion. Services fees increased 18% to $2.28 billion.
保费下降3.2％至354.2亿美元，产品收入增长14％至55.3亿美元。服务费增长18％，至22.8亿美元。
"Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which underpin our long-term targets," said Gail Boudreaux, President and CEO.
“第二季度的业绩反映了我们多样化的业务和在我们行业动态时期的战略计划的谨慎执行的力量，因为我们坚定地致力于改善人类的健康状况。我们已谨慎维持全年展望，并对我们的健康福利和 Carelon 业务的盈利能力有信心，这是我们长期目标的基础，”美国医疗保健管理公司（HMO）Elevance Health 的总裁兼CEO Gail Boudreaux表示。
Profit rose 24% to $2.3 billion, or $9.85 a share. Per-share adjusted earnings reached $10.12, beating consensus of $10.01.
利润增长了24％，至23亿美元，每股收益为9.85美元。每股调整后的盈利达到10.12美元，超过了10.01美元的共识。
The benefit expense ratio was 86.3%, an improvement of 10 basis points, driven primarily by premium rate adjustments to cover medical cost trends in the Health Benefits business and disciplined commercial underwriting.
受健康福利业务中医疗成本趋势的保费调整和商业核保纪律的推动，受益费用比率为86.3％，较去年同期提高了10个基点。
Medical membership totaled approximately 45.8 million, a decrease of 5% compared to the prior year quarter, driven by attrition in Medicaid business associated with eligibility redeterminations and footprint adjustments, primarily in the first quarter.
医保会员总数约为4580万，与上年同期相比下降了5％，主要是由于资格重新确定和足迹调整导致医疗补助业务流失，主要发生在第一季度。
Medicaid enrollment dropped 23% to 9 million in the second quarter compared to 11.7 million a year ago.
第二季度医疗补助保险登记人数从去年同期的1170万下降了23％至900万。
These losses were partially offset by growth in Affordable Care Act health plans and commercial Employer Group fee-based membership.
这些损失部分抵消了 Affordable Care Act 健康计划和商业雇主小组费用基础的会员增长。
Reuters notes that Unlike rivals UnitedHealth Group Inc (NYSE:UNH) and Humana Inc (NYSE:HUM), Elevance is less exposed to government-backed Medicare Advantage plans for people aged 65 and older and banks more on commercial and Medicaid health plans.
路透社指出，与竞争对手美国联合健康集团股份有限公司（NYSE：UNH）和Humana Inc（NYSE：HUM）不同，Elevance less 受政府支持的65岁及以上人群的 Medicare Advantage 计划的影响，更依赖于商业和医疗补助健康计划。
Operating revenue at its Carelon division was $13.3 billion, up by 10% year-over-year.
其 Carelon 部门的营业收入为133亿美元，同比增长10％。
Guidance: Elevance Health expects GAAP net income per diluted share of at least $34.05 in 2024 and reaffirms adjusted EPS guidance of at least $37.20 versus consensus Of $37.28.
指引：Elevance Health 预计 2024 年 GAAP 每股稀释净收益至少为34.05美元，重申至少为37.20美元的调整后每股收益指引，而共识为37.28美元。
Price Action: ELV shares are down 3.82% at $532.00 during the premarket session on the last check Wednesday.
价格动态：ELV股票在周三的盘前交易中下跌了3.82％，目前为532.00美元。
Image: Shutterstock/ REDPIXEL.PL
图片来源: shutterstock/REDPIXEL.PL
- Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs
- 强生（Johnson & Johnson）二季度收益：营业收入和利润因强劲的制药销售而超额，年度利润前景因并购成本而下调。